GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.
into the sixth amendment (the Sixth Amendment) to the Consulting
Agreement by and between George Siber (the Consultant) and the
Company, dated as of May 16, 2007 and as previously amended on
June 30, 2009, December 16, 2010, June 15, 2011, June 5, 2013 and
June 15, 2015 (the Consulting Agreement). to the Consulting
Agreement, the Consultant, a director on the Companys Board of
Directors, provides certain services to the Company as defined
and described in the Consulting Agreement (the Services). The
Sixth Amendment modifies the term of the Consulting Agreement and
the compensation to be paid to the Consultant in exchange for the
Services. to the Sixth Amendment, the Consulting Agreement is
extended to June 17, 2019 and the monthly fee paid by the Company
to the Consultant is increased from $5,208 to $9,833 per month.
without notice if the Consultant refuses or is unable to perform
the Services or is in breach of any material provision of the
Consulting Agreement. The Consulting Agreement may also be
terminated by either party upon fourteen days prior written
notice.
Consulting Agreement and the Sixth Amendment are general
descriptions only, do not purport to be complete, and are
qualified in their entirety by reference to the terms of the
Consulting Agreement, which is filed as an exhibit to the
Companys Registration Statement on Form S-1, filed on December
23, 2013 and of the Sixth Amendment, which is attached as Exhibit
10.1, to this Current Report on Form 8-K and incorporated herein
by reference.
Annual Meeting of Stockholders (the Meeting), at which a quorum
was present. At the Meeting, the stockholders of the Company
voted on the two proposals as follows: (i) to elect Mr. William
Clark, Mr. Ronald Cooper, and Dr. George Siber as Class III
members of the board of directors to serve until the Companys
2020 annual meeting of stockholders and until their successors
are duly elected and qualified (Proposal 1) and (ii) to ratify
the selection of Ernst Young LLP as the Companys independent
registered public accounting firm for the fiscal year ending
December 31, 2017 (Proposal 2).
the Meeting were as follows:
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|||||||
|
William Clark
|
18,621,362
|
60,580
|
5,736,425
|
||||||
|
Ronald Cooper
|
18,611,456
|
70,486
|
5,736,425
|
||||||
|
George Siber
|
13,046,263
|
5,635,679
|
5,736,425
|
||||||
the Meeting were as follows: 24,327,917 shares voted for, 49,828
shares voted against and 40,622 shares abstained from voting.
There were no broker non-votes with respect to Proposal 2.
About GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA)
Genocea Biosciences, Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment. It has one product candidate in Phase II clinical development: GEN-003, which is a therapeutic vaccine or immunotherapy for the treatment of genital herpes infections. It has pre-clinical development programs, which include GEN-001, which is indicated for the treatment of chlamydia prophylaxis, and GEN-002, which indicated for the treatment of genital herpes prophylaxis both of which are in pre-clinical stage of development. The Company’s pipeline also includes GEN-005, which is under malaria prophylaxis, Epstein-Barr virus and immuno-oncology programs in research stage of development.
